Articles On Telix Pharmaceuticals (ASX:TLX)
Title | Source | Codes | Date |
---|---|---|---|
ScoPo’s Powerplays: ASX health stocks up for second week, investors get reason to smile
Mach 7 announces patent infringement lawsuit settled in its favour Lumos Diagnostics tanks after device submission for FebriDX rejected by US FDA Three companies announce major milestones in clinical trials Healthcare and life sciences e... |
Stockhead | TLX | 1 year ago |
“Your Stock Request” – 14 July 2022
“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o... |
Fairmont Equities | TLX | 1 year ago |
How did ASX biotech shares perform in FY22?
ASX biotech shares were hammered in FY22 with the sector facing heavy losses, in line with the wider technology sector. The ETFs S&P Biotech ETF (ASX: CURE), an index fund tracking the global biotech sector, is down almost 24% this y... |
Motley Fool | TLX | 1 year ago |
Telix Pharmaceuticals announces major leadership appointment
Telix Pharmaceuticals (ASX:TLX) has announced the appointment of a CEO for its Americas business and dosed the final patient and completed recruitment into the pivotal Phase 3 study, ZIRCON. |
BiotechDispatch | TLX | 1 year ago |
Telix Pharmaceuticals (ASX:TLX) recruits Kevin Richardson as CEO Telix Americas
Telix Pharmaceuticals (TLX) appoints Kevin Richardson to the role of CEO Telix Americas The senior global executive will step into the position from today, bringing with him 25 years of experience in the healthcare industry Dr Christian Be... |
themarketherald.com.au | TLX | 1 year ago |
ASX Health Stocks: Lumos down 65pc on FDA rejection; and is Hexima belly-up after Phase 2 readout?
Lumos’ FebriDX was rejected by the FDA Hexima hurt by unexpected readout from Phase 2 trial Anteris reports good progress on DurAVR study Some unexpected news have driven a couple ASX healthcare stocks down by double digits this morning.... |
Stockhead | TLX | 1 year ago |
Lunch Report: 11 July, 2022
ShareCafeLunch Report: 11 July, 2022 by Melissa Darmawan The fall in materials and information tech led the retreat on the Australian sharemarket as gains in energy and financial stocks weren’t enough to offset the decline. At noon, the S... |
ShareCafe | TLX | 1 year ago |
ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment
MELBOURNE, Australia, July 11, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has dosed the final patient and completed recruitment into the Phase III pivotal study ZIRCON (Zircon... |
FNArena | TLX | 1 year ago |
Kevin Richardson appointed as CEO, Telix Americas
MELBOURNE and INDIANAPOLIS, July 11, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce that Kevin Richardson, a senior global executive with a career focus on sales, marketing and bus... |
FNArena | TLX | 1 year ago |
Bell Potter names 2 of the best ASX healthcare shares to buy in FY23
This month Iâve been looking at a number of shares that Bell Potter has rated as its top picks for FY 2023. You can read about its tech picks here and its energy picks here. On this occasion, letâs take a look at a couple of ASX health... |
Motley Fool | TLX | 1 year ago |
Telix Pharmaceuticals (ASX:TLX) signs licence and distribution agreement for Illuccix
Telix Pharmaceuticals (TLX) signs a licence and distribution agreement with Isologic Innovative Pharmaceuticals for its investigational prostate cancer imaging agent Illuccix Under the agreement, Isologic will be the commercial distributor... |
themarketherald.com.au | TLX | 1 year ago |
ASX Update: 19-month low as pandemic gains shrivel
Aussie shares sank to their lowest level since November 2020 as recession fears continued to batter financial markets. The S&P/ASX 200 dived 136 points or 2.07 per cent towards a sixth straight loss. Barring a miraculous afternoon re... |
themarketherald.com.au | TLX | 1 year ago |
Telix and Invicro Advance AI Partnership
MELBOURNE, Australia and BOSTON, June 14, 2022 /PRNewswire/ – Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has advanced a partnership with Invicro LLC (Invicro), a global, industry-leading imaging... |
FNArena | TLX | 1 year ago |
Telix and Invicro Advance AI Partnership
MELBOURNE, Australia and BOSTON, June 14, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has advanced a partnership with Invicro LLC (Invicro), a global, industry-leading imaging... |
FNArena | TLX | 1 year ago |
Telix and RefleXion expand partnership for prostate cancer treatment
Telix Pharmaceuticals (ASX:TLX) and US-based RefleXion Medical have signed a new co-development and commercialisation agreement. |
BiotechDispatch | TLX | 1 year ago |
Jubilant Radiopharma Joins Illuccix® Pharmacy Partner Network
MELBOURNE, Australia and INDIANAPOLIS, June 13, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce that its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga... |
FNArena | TLX | 1 year ago |
Telix and RefleXion Expand Partnership for Prostate Cancer Treatment
MELBOURNE, Australia and INDIANAPOLIS, June 10, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RefleXion Medical, Inc. (Hayward, California, U.S.) (RefleXion) today announced the signing of a co-dev... |
FNArena | TLX | 1 year ago |
Lunch Report: 10 June, 2022
ShareCafeLunch Report: 10 June, 2022 by Lauren Evans The Aussie sharemarket is off to another weak start following a red finish on Wall Street. Australian shares are on track for their largest weekly decline this year as markets digest th... |
ShareCafe | TLX | 1 year ago |
Telix Pharmaceuticals (ASX:TLX) expands partnership with RefleXion for prostate cancer treatment
Telix Pharmaceuticals (TLX) signs a partnership for prostate cancer treatment with RefleXion Medical The parties agreed to sign a co-development and commercialisation agreement to expand the use of Telix’s prostate cancer imaging agent Ill... |
themarketherald.com.au | TLX | 1 year ago |
Stocks of the Hour: Bubs Australia, Telix Pharmaceuticals, Terracom & Medallion Metals
10 Jun 2022 - A snapshot of the stocks on the move featuring Bubs Australia (ASX:BUB), Telix Pharmaceuticals (ASX:TLX), Terracom (ASX:TER) & Medallion Metals (ASX:MM8). |
FNN | TLX | 1 year ago |
ASX Health Stocks: Telix seeks FDA approval for Illucix; CAR T releases viral vector
Telix Pharma’s Illucix could be used in BgRT radiotherapies in the US Chimeric Therapeutics advances its CAR T therapy program Telix expands partnership with US-based RefleXion Telix Pharma (ASX:TLX) has expanded its partnership with Cali... |
Stockhead | TLX | 1 year ago |
Telix Pharmaceuticals reports significant R&D tax refund
Telix Pharmaceuticals (ASX:TLX) has received a $17.25 million R&D tax refund from the federal government for eligible activities undertaken in the year ended 31 December 2021. |
BiotechDispatch | TLX | 1 year ago |
Telix to Present at Jefferies Healthcare Conference
MELBOURNE, Australia and INDIANAPOLIS, June 7, 2022 /PRNewswire/ – Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic pr... |
FNArena | TLX | 1 year ago |
Evening Report: 7 June, 2022
ShareCafeEvening Report: 7 June, 2022 by Melissa Darmawan The cost of living is set to rise after the Reserve Bank of Australia (RBA) raised the cash rate by 50 basis points versus the expected 40, sending the ASX 200 to a three week low,... |
ShareCafe | TLX | 1 year ago |
CSL to ACL: How top 10 ASX All Ords healthcare stocks are faring?
Highlights XAO or All Ords entails the 500 largest companies on the ASX XAO is down by nearly 5.19% on a YTD basis, as of 7 June 2022 The healthcare space has witnessed great developments amid the COVID-19 outbreak. The All Ordina... |
Kalkine Media | TLX | 1 year ago |
ASX Close: Jumbo rate rise drives stocks to two-week low
Australian shares suffered their heaviest loss in more than three weeks after the Reserve Bank raised its benchmark rate by 50 basis points to 0.85 per cent. The dollar jumped and shares slumped when news of the bumper hike was released.... |
themarketherald.com.au | TLX | 1 year ago |
Stocks of the Hour: Yancoal, GQG Partners, Telix, Kingston Resources
07 Jun 2022 - A snapshot of the stocks on the move featuring, Yancoal (ASX:YAL), GQG Partners (ASX:GQG), Telix Pharmaceuticals (ASX:TLX), and Kingston Resources (ASX:KSN). |
FNN | TLX | 1 year ago |
ASX Update: Consumer gloom, rate doubts weigh on shares
Shares fell for a second day as downbeat economic data underlined cost of living pressures ahead of an expected rate rise this afternoon. A broad sell-off drove the S&P/ASX 200 down 63 points or 0.88 per cent by mid-session. All... |
themarketherald.com.au | TLX | 1 year ago |
ASX 200 falls nearly 0.60% as banks drag ahead of RBA’s rate decision
Highlights The Australian equity market opened lower today as the benchmark index ASX 200 index was down 0.58% at 7,164.80 points in the opening hours of trading All the top four ASX-listed banks slipped into the red ahead of RBA’s int... |
Kalkine Media | TLX | 1 year ago |
Market highlights and 5 ASX Small Caps to watch on Tuesday
The ASX 200 is set to open lower this morning RBA will announce interest rates decision at 2.30pm AEST Bitcoin is back over US$31k again Aussie shares will open marginally lower this morning ahead of the RBA decision, despite US stocks ri... |
Stockhead | TLX | 1 year ago |
Telix Showcasing Innovation in Theranostics at SNMMI
MELBOURNE, Australia and INDIANAPOLIS, June 7, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its presence at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting... |
FNArena | TLX | 1 year ago |
ASX Close: Stocks retreat as investors prepare for higher rates
The share market dropped 0.8 per cent following pressure on US stocks as the threat of significantly higher interest rates dampened buying interest. The S&P/ASX 200 declined 58 points to 7165. Tech stocks led a sell-off in sectors... |
themarketherald.com.au | TLX | 1 year ago |
Evening Report: 1 June, 2022
ShareCafeEvening Report: 1 June, 2022 by Lauren Evans The Australian sharemarket held on to its gains in the afternoon session despite a big drop in lithium miners. Communication services led the pack up nearly 2 per cent, followed by fin... |
ShareCafe | TLX | 1 year ago |
ASX Health Stocks: Mesoblast’s Q3 revenues, Osprey restructures business to reduce debt
Mesoblast reports quarterly trading revenues Telix appoints new executives Osprey restructures business, in trading halt Cellular medicines specialist Mesoblast (ASX:MSB) says its revenues in the third quarter increased by 5% on the same... |
Stockhead | TLX | 1 year ago |
Lunch Report: 1 June, 2022
ShareCafeLunch Report: 1 June, 2022 by Lauren Evans The Aussie sharemarket is pushing higher this morning after Wall Street fell overnight amid inflation and recession fears across the globe. Most sectors are showing gains, with the excep... |
ShareCafe | TLX | 1 year ago |
Telix Pharmaceuticals (ASX:TLX) reshuffles Board to transition company into next phase of growth
Telix Pharmaceuticals (TLX) announces a number of changes to its executive leadership team to enable the company to move into its next phase of growth The company has appointed Darren Smith as Chief Financial Officer, replacing Doug Cubbin... |
themarketherald.com.au | TLX | 1 year ago |
Telix Pharmaceuticals (ASX:TLX) announces leadership changes
01 Jun 2022 - Darren Smith will take over Doug Cubbin as chief financial officer of Telix Pharmaceuticals (ASX:TLX). |
FNN | TLX | 1 year ago |
Evening Report: 30 May, 2022
ShareCafeEvening Report: 30 May, 2022 by Lauren Evans The ASX 200 rose for a second successive day led by technology, materials and bank shares. At the closing bell, the index was 1.5 per cent or 104 points higher at 7,287, its best perfo... |
ShareCafe | TLX | 1 year ago |
ASX Large Caps: Tech index climbs 4pc amid hopes US inflation may have peaked
ASX 200 was up 1.3% today, led by Tech which jumped 4% A2M rose 10% after Bubs got export deal with the US AGL Energy cancels coal demerger plan A surge in Tech stocks led the ASX to a 1.3% higher close today, following a strong rally... |
Stockhead | TLX | 1 year ago |
Why Alkane Resources, Block, Bubs, and Telix shares are storming higher
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has followed Wall Street’s lead and is charging higher. At the time of writing, the benchmark index is up 1.1% to 7,259.6 points. Four ASX shares that are climbing more than most tod... |
Motley Fool | TLX | 1 year ago |
Lunch Report: 30 May, 2022
ShareCafeLunch Report: 30 May, 2022 by Melissa Darmawan Australian shares jumped to a three week high after a strong lead from Wall St. Every sector is rallying, bar utilities after news from AGL. The optimism is led by technology shares,... |
ShareCafe | TLX | 1 year ago |
Stocks of the Hour: Telix Pharmaceuticals, Australian Unity Office Fund & Yancoal
30 May 2022 - A snapshot of the stocks on the move featuring Telix Pharmaceuticals (ASX:TLX), Australian Unity Office Fund (ASX:AOF) & Yancoal (ASX:YAL). |
FNN | TLX | 1 year ago |
ASX Health Stocks: Invion demonstrates efficacy, Biotron gets feedback from the FDA
Invion demonstrates high efficacy of INV043 when used as a combined therapy Biotron gets positive feedback from US FDA Biome stocks its Probiotics range on Priceline’s shelves Invion demonstrates efficacy Cancer fighter Invion (ASX:IVX) w... |
Stockhead | TLX | 1 year ago |
Illuccix® Reimbursement Milestone and Launch Updates: Pass-Through Status Granted in the U.S.
MELBOURNE, Australia and INDIANAPOLIS, May 30, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on the U.S. and Australian launch and reimbursement status for its prostate cancer i... |
FNArena | TLX | 1 year ago |
‘We’re close to the bottom’: Expert flags share market sectors to buy before the rally
Friday has brought good news for embattled investors. DeVere Group CEO and founder Nigel Green has tipped that major global indexes – such as the S&P/ASX 200 Index (ASX: XJO) – could be nearing their lowest point and getting ready to r... |
Motley Fool | TLX | 1 year ago |
Lunch Report: 18 May, 2022
ShareCafeLunch Report: 18 May, 2022 by Melissa Darmawan Materials lift ASX higher for 4th day Australian shares are on track to continue its winning streak for its fourth straight day after taking a strong lead from Wall St. The local ind... |
ShareCafe | TLX | 1 year ago |
The Overnight Report: A Time To Rally
World Overnight SPI Overnight 7181.00 + 70.00 0.98% S&P ASX 200 7112.50 + 19.50 0.27% S&P500 4088.85 + 80.84 2.02% Nasdaq Comp 11984.52 + 321.73 2.76% DJIA 32654.59 + 431.17 1.34% S&P500 VIX 26.10 – 1.37 – 4.99%... |
FNArena | TLX | 1 year ago |
ASX Today: US rebound gathers pace as recession fears fade
Australian shares were poised to open higher for a fourth day after strong retail sales doused fears of an economic slowdown in the US. Wall Street’s main indices closed sharply higher as a rebound from six weeks of steady decline gath... |
themarketherald.com.au | TLX | 1 year ago |
ASX Today: Bright start as US bounces, Shanghai reopens
Australian stocks were poised to open higher as lockdown news out of China over the weekend added to positive leads from Wall Street and commodity markets. ASX futures rallied 54 points or 0.77 per cent on Friday night as US stocks sur... |
themarketherald.com.au | TLX | 1 year ago |
ASX Close: Sharp rebound trims a fourth week of losses
Australian shares rebounded strongly this session but could not avert a fourth straight weekly decline as financial markets continued to factor in the risk of a global slowdown as rates rise and China pursues zero-Covid. An end-of-week r... |
themarketherald.com.au | TLX | 1 year ago |